Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT04007055
PHASE3

The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

Sponsor: Marissa Jarosinski

View on ClinicalTrials.gov

Summary

This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.

Official title: The Value of Screening for "High on Treatment Platelet Reactivity" in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

31

Start Date

2019-08-09

Completion Date

2024-03-28

Last Updated

2026-07-06

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

Point of care screening for HPR

HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234

DRUG

Ticagrelor 90mg

Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily

Locations (1)

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States